Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

The National Rosacea Society has opened its applications for research funding as the grant program celebrates its 25th ...

Rosacea is more common among fair-skinned people ages 30 to 50 years. It's slightly more common in females rather than males. Even so, rosacea can develop at any age, even during childhood. These ...

Macular telangiectasia, sometimes referred to as idiopathic juxtafoveal macular telangiectasia, is a disease that affects the part of the eye called the macula, causing degradation or loss of central ...

Journey Medical plans to highlight the launch of Emrosi™ and showcase its line of prescription dermatology products. The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in ...

Living with skin that’s prone to rosacea isn’t easy. Trying to pin down a trigger for your redness can be exhausting: It could be stress, extreme temperatures, spicy foods, fragrance ...

Department of Dermatology, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650032, Yunnan, China ...

We thank Michèl Willemsen and colleagues for their interest in the ATTeST trial of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia. 1 The two doses studied in ...

aDepartment of Pediatrics (Pediatric Neurology), Amalia Children's Hospital, Radboud University Medical Center, Nijmegen 6500, Netherlands ...

The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November 2024. Interested parties are invited to visit Journey Medical’s booth 2181 to learn about ...